ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

19 مايو 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

10 مايو 2022 06:00:02 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

03 مايو 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

27 أبريل 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

26 أبريل 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

07 أبريل 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit

28 مارس 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference

15 مارس 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum

09 مارس 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

04 مارس 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

10 فبراير 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results

09 فبراير 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

04 فبراير 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022

03 فبراير 2022 06:00:01 بحسب Nasdaq GlobeNewswire

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome

01 فبراير 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71

10 يناير 2022 06:00:03 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer

06 يناير 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

05 يناير 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference

14 ديسمبر 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference

29 نوفمبر 2021 06:00:01 بحسب Nasdaq GlobeNewswire